Brentuximab vedotin (Adcetris)

At a glance

Brentuximab vedotin (Adcetris) is an antibody–drug conjugate, often shortened to ADC. It combines an antibody that recognises a target on cells with a cell-killing medicine. It is given by a trained team through a drip into a vein. Although it is targeted treatment, it can affect healthy tissues and needs careful monitoring.

Changes in sensation, strength or balance deserve early attention during this treatment. Brentuximab can injure peripheral nerves, and symptoms may build up over several doses. Reporting trouble with buttons, walking or handling hot objects helps the team act before daily function is seriously affected.

Follow your own treatment calendar and the advice from your care team. Keep your medicine names and treatment dates handy to share with other clinicians.

How it works

Brentuximab recognises a cell-surface protein called CD30. It carries monomethyl auristatin E, or MMAE, which disrupts the internal structures needed for cells to divide. Once the conjugate is taken into a target cell, the attached drug can be released. CD30-directed treatment is different from a checkpoint inhibitor or an unlinked chemotherapy infusion.

The antibody, its chemical link and the attached medicine form one product. They are not separate medicines that you can take in different amounts yourself. Targeting helps deliver treatment to particular cells, but it does not mean that only cancer cells are affected. Side effects can come from the attached medicine, the antibody, your existing illness or accompanying treatment.

An ADC is different from an immune checkpoint inhibitor, even when both are given in the same treatment plan. A reaction or noticeable side effect is not proof that an ADC is working. Equally, having few side effects does not mean that treatment has failed.

Is this treatment suitable for me?

Brentuximab vedotin is used in selected Hodgkin lymphomas, systemic anaplastic large cell lymphoma and certain previously treated cutaneous lymphomas. In the US, first-line use with cyclophosphamide, doxorubicin and prednisone (CHP) also includes other CD30-expressing peripheral T-cell lymphomas in adults. The European first-line CHP indication is limited to adults with systemic anaplastic large cell lymphoma. Your team checks the exact lymphoma subtype, treatment setting and applicable regional approval. Some treatment plans also use it with lenalidomide and rituximab for selected relapsed or refractory large B-cell lymphomas after at least two previous lines of treatment when transplant or CAR-T therapy is unsuitable. Your oncologist will advise whether it is suitable for you, taking account of your cancer type, relevant test results, previous treatment, overall health and the applicable prescribing information and regulatory guidance in your country.

The team considers CD30-related findings where relevant, previous therapies, existing nerve symptoms and kidney or liver function. Severe kidney impairment or significant liver impairment can increase exposure to the attached drug and may make treatment unsuitable. The accompanying regimen matters: brentuximab must not be combined with bleomycin because of lung toxicity.

The discussion should cover the aim of treatment, the alternatives, likely appointments and how benefit will be assessed. A target found in a sample is one part of this decision; it does not guarantee a response. Tell the team what matters to you, including independence, work, caring responsibilities and the practical support available at home.

Before treatment

Bring a complete list of prescribed and non-prescribed medicines, vitamins, herbal products and allergies. Mention previous difficult reactions to infusions, infections, diabetes, liver or kidney problems and any pregnancy or breastfeeding. Explain symptoms you already have so a later change is easier to recognise.

Describe numbness, tingling, burning pain, weakness, falls or difficulty with fine hand movements before the first dose. Blood counts and liver and kidney tests establish a baseline. Pregnancy testing is needed before treatment if you could become pregnant. Explain previous lung problems, pancreatitis or severe abdominal illness. Infection-prevention treatment and growth-factor injections may be needed, especially in combination regimens.

A nurse or pharmacist should explain the supportive medicines and which ones start before the treatment day. Ask your team to help you plan when to take each medicine. Make sure you know how to reach your hospital's urgent oncology service outside clinic hours. You may find it helpful to save the instructions on your phone or keep a copy at home. A family member or friend can help you remember them.

Discuss fertility preservation before treatment if future parenthood matters to you. Tell the team about dental problems and planned procedures. A procedure may need to be timed around blood counts and infection risk. Do not postpone reporting an active dental infection while waiting for the next routine appointment.

How treatment is given

The infusion usually takes 30 minutes. Common schedules include 1.8 mg/kg every three weeks when used alone or in certain combinations, and 1.2 mg/kg every two weeks in an AVD-based plan. Some other combinations use a different starting amount, including a 1.2 mg/kg three-weekly schedule. The exact dose, maximum dose and number of cycles depend on the prescribed regimen and patient factors; paediatric plans require their own specialist prescription.

Brentuximab may be combined with other cancer medicines such as doxorubicin, vinblastine and dacarbazine, or with other specified combinations. Growth-factor support is required from the first cycle with the reviewed AVD, AVEPC, CHP and lenalidomide–rituximab combination plans to reduce serious low-white-cell complications. The BrECADD regimen has its own schedule, beginning growth-factor support on day 5 of each cycle. Preventive medicines before the infusion are particularly important after an earlier infusion reaction. Follow the unit’s observation plan.

Treatment is delivered through a cannula in a vein, a central line or an implanted port, depending on the plan and available access. Staff check the medicine, your identity, blood results and recent symptoms before starting. The appointment includes preparation and monitoring, so it will usually take longer than the infusion itself.

Tell the nurse immediately if you notice burning, pain, swelling, redness, leakage or tightness around the infusion site. These can mean medicine is leaking outside the vein. Do not wait for the drip to finish. At home, report a site that becomes more painful, blistered or discoloured, even if it looked normal when you left.

Also report flushing, itching, shivering, chest or back discomfort, wheezing, dizziness or swelling during treatment. Staff can stop or slow the infusion and assess you. Do not adjust the pump or line yourself. If a line remains in place, follow its cleaning and dressing instructions and report fever, tenderness or drainage around it.

If an appointment is missed, contact the treatment unit to arrange the next dose. Do not simply wait for the following cycle or seek an extra dose elsewhere. The correct restart date depends on why the dose was missed, the treatment schedule and recovery from side effects.

Monitoring your treatment

Blood tests usually check infection-fighting cells, red cells, platelets, kidney function and liver function. Some abnormalities cause no early symptoms. A reassuring blood test does not make a new symptom safe to ignore, and feeling well is not a reason to miss monitoring.

At each review, describe changes in sensation and function, not just pain. Nerve toxicity can require a pause, lower dose or permanent discontinuation. Blood counts are checked before doses, and liver tests and blood glucose are monitored. Disease assessment may include imaging and other tests selected for the treatment plan. Some courses have a fixed maximum number of cycles; others are adjusted for response and tolerance.

Your team compares examinations, symptoms and relevant scans or disease tests over time. Ask when the first response assessment is planned and what the result could change. A treatment break or lower dose may protect you from accumulating harm while allowing further treatment. It is not automatically evidence that the cancer has worsened. Never try to compensate for a reduced dose with supplements or closer appointments.

Common side effects

Side effects vary between people and between treatment combinations. You may experience several, a few or none of those described. Tell the team about symptoms that interfere with eating, sleeping, walking or usual tasks; a problem does not need to be severe before support is worthwhile.

Numbness, tingling and weakness

Peripheral neuropathy means damage to nerves outside the brain and spinal cord. It may feel like pins and needles, burning or reduced sensation in the hands and feet. Report new difficulty doing up buttons, stumbling or reduced grip promptly. Use well-fitting footwear, inspect feet for injury and be careful with hot water or sharp objects. Do not wait until symptoms are painful.

Aches and changes in hair

Muscle or joint discomfort can occur. Check which pain relief is suitable, particularly if platelets or kidney function are affected. Hair thinning or loss may occur, and accompanying chemotherapy can make it more marked. Discuss gentle scalp care and available support before treatment if this is a concern.

Tiredness and reduced stamina

Plan important tasks for the part of the day when you have most energy and accept practical help. Short periods of gentle activity can be useful, with rest between them. Sudden marked weakness, breathlessness, dizziness or a racing heart needs assessment for causes such as anaemia, infection or dehydration. Do not assume every new limitation is ordinary treatment fatigue.

Nausea, appetite and bowel changes

Take prescribed anti-sickness medicines on the agreed schedule. Small regular meals, cool foods and frequent sips can be easier to manage. Tell the team if you cannot keep medicines or fluids down, are passing little urine or are losing weight. A dietitian can help when eating becomes difficult.

Record loose stools and whether there is pain, blood or fever. Severe diarrhoea, repeated vomiting or a swollen painful abdomen needs prompt advice. Constipation can be worsened by anti-sickness drugs and pain relief; use the bowel plan your team recommends. Do not repeatedly add laxatives or anti-diarrhoeal medicines without checking when there is significant pain or other new illness.

Low blood counts

A low white cell count can make infection progress quickly. Follow the urgent-help instructions below. Low red cells can cause tiredness, pallor or breathlessness; sometimes transfusions are needed. Low platelets can cause easy bruising, nosebleeds, bleeding gums or tiny red-purple spots. Report new bleeding and avoid starting aspirin or anti-inflammatory painkillers without checking. Do not stop a prescribed blood thinner yourself; the team must balance bleeding and clotting risks.

Mouth comfort and skin care

Use a soft toothbrush and the mouth-care products advised by your team. Report ulcers, white patches or soreness that limits eating, because infection or dehydration may need treatment. Avoid very hot, acidic or spicy foods if they sting. Moisturise dry skin with a simple fragrance-free product and protect it from strong sunlight. Painful skin, blisters or rapidly worsening redness need medical assessment rather than a new cosmetic product.

Important side effects

Lung inflammation

New cough, breathlessness, wheeze or worsening oxygen levels needs prompt assessment. Infection and drug-related inflammation can look similar. Severe breathing difficulty is an emergency. The combination with bleomycin is contraindicated because of increased lung toxicity. New or worsening lung symptoms require withholding brentuximab while the team investigates and until symptoms improve.

Pancreatitis, bowel complications and liver injury

Severe persistent upper abdominal pain, pain spreading to the back, repeated vomiting, a swollen rigid abdomen, black stools or jaundice needs urgent medical attention. These may signal inflammation of the pancreas, serious bowel injury, bleeding or liver injury. Do not manage severe abdominal pain solely with extra painkillers.

Rare brain infection and severe skin reactions

A rare infection called progressive multifocal leukoencephalopathy, or PML, can cause new weakness, clumsiness, memory or personality changes, speech difficulty or visual changes. Report these promptly. Suspected PML requires withholding treatment; confirmed PML requires stopping it. Severe blistering or peeling skin, especially with mouth sores or fever, also requires immediate assessment. Report a rash with fever, facial swelling or other organ symptoms even without blisters: this can be a serious reaction called DRESS. Confirmed Stevens–Johnson syndrome, toxic epidermal necrolysis or DRESS requires stopping treatment.

High blood glucose

Blood glucose can rise, including in people without previous diabetes. Marked thirst, frequent urination or unexpected weakness needs prompt advice. Vomiting, abdominal pain, deep or rapid breathing, drowsiness or confusion may indicate ketoacidosis and needs emergency assessment. The team monitors glucose and treats raised levels.

Tumour lysis syndrome

Rapid breakdown of cancer cells can disturb salts in the blood and kidney function. Higher-risk patients need preventive medicines, fluids and close blood monitoring. Reduced urine, severe weakness, muscle cramps, palpitations or confusion must be reported urgently.

Severe infection or an allergic reaction

A serious infection can occur even without a high temperature, especially if steroids or fever-reducing medicines are being taken. New confusion, marked drowsiness, rapid breathing or collapse requires emergency care. Sudden throat swelling, severe wheezing or faintness can indicate a severe allergic reaction. These symptoms should not be managed by waiting at home for the next scheduled review. Anaphylaxis requires immediate treatment and permanent discontinuation of brentuximab.

Other medicines and vaccinations

Bleomycin must not be given with brentuximab. Strong CYP3A inhibitors or inducers can alter exposure to its attached drug; the pharmacist should check medicines such as certain antifungals, antibiotics, antiviral treatments and seizure medicines. Do not stop an essential anti-infective yourself. Other nerve-toxic medicines can add to neuropathy, so include previous and current treatment in the medication review.

Ask the oncology pharmacist to check new prescriptions, over-the-counter remedies and herbal or traditional products. Products described as natural are not necessarily safe with cancer treatment. Do not use an unproven supplement in place of an essential supportive medicine. Keep the team informed about medicines prescribed by other specialists so that advice is coordinated.

Discuss influenza, COVID-19 and other vaccines with the team. Non-live vaccines may be suitable, although the response can be reduced during treatment. Live vaccines require specific specialist advice. Timing after treatment depends on immune recovery and the complete regimen; there is no single waiting interval that is correct for every ADC-treated patient.

Everyday life

Eating does not determine absorption of this intravenous medicine. Aim for enough food and fluids, adjusting for nausea and following any kidney, heart or diabetes restrictions. Avoid a restrictive anticancer diet that causes weight loss. Discuss alcohol with the team, particularly if liver tests are abnormal or other medicines cause sedation.

Work may remain possible with flexible hours and time for appointments. Increase activity gradually and avoid tasks that become unsafe because of fatigue, poor balance or impaired vision. Do not drive if dizzy, sleepy, visually affected or unable to use the pedals safely. Sedating premedicines can also affect driving, so arrange transport for early appointments until you know the plan.

If sensation or balance changes, reduce fall hazards at home and ask about physiotherapy or occupational therapy. Avoid driving when foot sensation, strength or coordination is impaired. Do not use a heat pad on numb skin because burns may go unnoticed. Record how symptoms affect tasks so dose decisions reflect their practical impact.

Discuss travel before booking, especially long journeys or travel far from urgent care. Carry your treatment summary and enough supportive medicines. Use careful hand hygiene and food safety; avoid close contact with people who are clearly infectious. Complete social isolation is not automatically required. Ask about additional precautions when blood counts are very low.

Sex is often possible if comfortable, with the pregnancy precautions below and any advice about infection or bleeding. Ask the team whether barrier protection is needed after a dose to reduce exposure to drug residues in body fluids; the interval depends on the treatment. Caregivers cleaning urine, stool or vomit should follow the unit's handling advice, wear gloves when instructed and wash their hands afterwards. Keep medicines away from children and pets.

Fertility, pregnancy and breastfeeding

Use effective contraception during treatment. Current US instructions specify two months after the final dose for a treated person who could become pregnant and four months for a treated man with a partner who could become pregnant. EU information advises two effective contraceptive methods for women during treatment and for six months afterwards, and advises men not to father a child for six months after treatment. Obtain the interval applicable to your product and full regimen; do not choose the shortest period yourself. Breastfeeding is not recommended during treatment. A post-treatment restart requires specialist advice because a single fixed interval is not specified consistently in the checked labels.

Pregnancy should be discussed before treatment and reported promptly if it occurs or is suspected. Loss of periods does not reliably mean pregnancy is impossible. Vomiting or severe diarrhoea can interfere with oral contraception; seek advice about additional protection if this happens. Accompanying medicines may require longer precautions than the ADC itself, so obtain one clear end date for the complete regimen.

Fertility may be affected by treatment and previous therapies, and recovery cannot be guaranteed. Discuss sperm, egg or embryo preservation before starting when feasible. The interval for avoiding pregnancy is a safety precaution and does not itself establish whether fertility has recovered.

After treatment

Nerve symptoms can improve slowly after treatment and may persist. Continue reporting changes and ask for rehabilitation or symptom treatment. New neurological symptoms should not automatically be labelled as old neuropathy, particularly if there is weakness on one side, speech difficulty or cognitive change.

Keep attending the recommended blood tests, scans and clinical reviews. Retain a treatment summary with the exact ADC name, dates, significant reactions and any ongoing medication. Tell new clinicians about past treatment when an unexplained symptom is assessed. Continue contraception, breastfeeding restrictions and prescribed supportive medicines for their own specified periods, counted from the relevant final dose.

Recovery can be gradual and may involve physical rehabilitation, dietary support or help with anxiety and sleep. A follow-up visit is also an opportunity to discuss returning to work, travel and persistent symptoms. New severe symptoms still need urgent assessment between appointments; finishing treatment does not remove the need for the urgent-care plan.

Common questions